Katie is one of Aceragen’s leads on patient engagement. She has served as a clinical genetic counselor and lysosomal storage disease program coordinator in the Rare Disease Institute at Children’s National Hospital. During her time there, she supported patients through diagnosis and long-term management as well as managed multiple clinical trials, natural history studies and
John was the Co-Founder, President and CEO of Aceragen as well as a member of the Board of Directors. Following Aceragen’s merger with Idera Pharmaceuticals in 2022, he was appointed Idera’s President and CEO and joined its Board of Directors. He has extensive experience in the orphan and rare disease field, having spent a significant
Dan leads business operations at Aceragen. He has 28 years of global pharmaceutical experience in manufacturing, supply chain management, strategic sourcing, distribution and business development. During his career, he participated in the successful launch and introduction of more than 30 global products including Zenpep®, Lamictal®, Amrix®, Canasa® and Metadate CD®. Before joining Aceragen, Dan served
Brian leads technical operations at Aceragen and oversees facilities and equipment. In his previous position at US WorldMeds, he was a member of the executive leadership team and was responsible for the global manufacturing operations, supply chain and quality teams. During his tenure, the company achieved multiple product approvals and launches, most notably Lucemyra and
Andy has an extensive professional history of leading the finances for pharmaceutical, public health and biotech companies. Andy was a founder of Guilford Pharmaceuticals. He later joined Odyssey Pharmaceuticals and Infraredx, Inc., in high-level financial roles. Apart from Andy’s background in finance he brings leadership and administrative experience to Aceragen. He has advised CEOs on
Pamela is an experienced regulatory affairs professional with 14 years of industry experience in global regulatory Chemistry, Manufacturing and Controls (CMC) as well as analytical development. She implements regulatory strategies and risk assessments for Aceragen product development teams from pre-IND to post-approval. Prior to joining Aceragen, Pamela has worked directly on approved drug products in
